Home » Stocks » OBSV

ObsEva SA (OBSV)

Stock Price: $2.52 USD -0.07 (-2.70%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $2.55 +0.03 (1.19%) Jul 30, 7:59 PM
Market Cap 187.88M
Revenue (ttm) 19,000
Net Income (ttm) -81.11M
Shares Out 74.41M
EPS (ttm) -1.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $2.52
Previous Close $2.59
Change ($) -0.07
Change (%) -2.70%
Day's Open 2.55
Day's Range 2.49 - 2.60
Day's Volume 1,609,854
52-Week Range 1.86 - 5.55

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) i ; agent is being studied in an area of significant unmet need

3 days ago - GlobeNewsWire

Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.

2 weeks ago - Zacks Investment Research

Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.

Other stocks mentioned: ATRS, GTBP, OCGN, ODT, PTN, SEEL
3 weeks ago - PennyStocks

-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia –

4 weeks ago - GlobeNewsWire

-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo transfer -

1 month ago - GlobeNewsWire

- D ata from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous p reterm labor to be discussed in an oral presentation -

1 month ago - GlobeNewsWire

Geneva, Switzerland  and Boston, MA –  May 31 , 202 1  – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive ...

1 month ago - GlobeNewsWire

Geneva, Switzerland and Boston, MA –  May 25 , 202 1  – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive h...

2 months ago - GlobeNewsWire

Swiss biopharma ObsEva is on course to introduce an oral treatment for uterine fibroids, which affect 80% of women by menopause. The post OBSV Stock: The Big Clinical Trial News Boosting ObsEva Today ap...

2 months ago - InvestorPlace

- PRIMROSE 1 76-week results confirm PRIMROSE 2 data showing sustained post- treatment effects and evidence of bone mineral density (BMD) recovery following 52 weeks of treatment -

2 months ago - GlobeNewsWire

GENEVA, Switzerland and BOSTON, MA – May 6 , 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive healt...

2 months ago - GlobeNewsWire

GENEVA, Switzerland and BOSTON, MA – April 30, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive heal...

3 months ago - GlobeNewsWire

- Long-term follow-up study to evaluate bone mineral density in women completing at least 20 weeks of treatment in Phase 3 PRIMROSE 1 or PRIMROSE 2 -

3 months ago - GlobeNewsWire

Geneva, Switzerland and Boston, MA –  April 22 , 202 1  – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive...

3 months ago - GlobeNewsWire

-Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21-

4 months ago - GlobeNewsWire

Geneva, Switzerland and Boston, MA – March 3, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive heal...

4 months ago - GlobeNewsWire

Penny stocks like BLU stock and OBSV stock are gaining traction with retail investors, especially as analyst sentiment heats up. The post Penny Stocks News: Why Little-Known Plays OBSV and BLU Are Climb...

Other stocks mentioned: BLU
5 months ago - InvestorPlace

5 months ago - GlobeNewsWire

Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.

Other stocks mentioned: ALNA, ALRN, MBIO, MCHX, MDWD, RWLK
5 months ago - InvestorPlace

There's an old saying that 'gaps refill'. And that means that these 7 penny stock Bubbles may be about to burst.

Other stocks mentioned: ABML, GHSI, NMGRF, SB, ISR, ZOM
6 months ago - InvestorPlace

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Other stocks mentioned: AMPH, AQUA, BBDC, BHVN, CFX, CRHM, GBT ...
6 months ago - Seeking Alpha

Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

ObsEva (OBSV) stock is soaring higher on Friday as shares see heavy trading despite there not being any noteworthy news today. The post OBSV Stock: 7 Things for ObsEva Investors to Know Before Investing...

6 months ago - InvestorPlace

In the last round, 36% of recipients saved the money, If you're planning the same with the second payment, here are seven stocks to buy with your stimulus check. The post 7 Stocks to Buy With That Secon...

Other stocks mentioned: APHA, JPM, LMT, NEM, NIO, STPK
6 months ago - InvestorPlace

Geneva, Switzerland and Boston, MA – January 7, 2021 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive he...

6 months ago - GlobeNewsWire

Geneva, Switzerland and Boston, MA – January 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's ...

6 months ago - GlobeNewsWire

 PRIMROSE 1 52-week results confirm the sustained efficacy and continued safety of linzagolix (Yselty®), with a potential best-in-class high-dose option (200 mg with add-back therapy [ABT])

7 months ago - GlobeNewsWire

Geneva, Switzerland and Boston, MA – December 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's...

7 months ago - GlobeNewsWire

ObsEva (OBSV) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids

8 months ago - GlobeNewsWire

Over 50% reduction of pre-term delivery within 48hrs of treatment in singleton pregnancy

8 months ago - GlobeNewsWire

Geneva, Switzerland and Boston, MA – November 13, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women'...

8 months ago - GlobeNewsWire

 Geneva, Switzerland and Boston, MA – November 9, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women'...

8 months ago - GlobeNewsWire

 Geneva, Switzerland and Boston, MA – 2 November, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women'...

8 months ago - GlobeNewsWire

 Geneva, Switzerland and Boston, MA – October 22, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproducti...

9 months ago - GlobeNewsWire

Geneva, Switzerland and Boston, MA – October 20, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductiv...

9 months ago - GlobeNewsWire

 ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Loumaye will ...

10 months ago - GlobeNewsWire

 GENEVA, Switzerland and BOSTON, MA (September 3, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) (“ObsEva” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing nove...

10 months ago - GlobeNewsWire

 Geneva, Switzerland and Boston, MA – August 7, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductiv...

11 months ago - GlobeNewsWire

 Primary endpoint successfully met in Phase 3 PRIMROSE 1 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids

11 months ago - GlobeNewsWire

 Geneva, Switzerland and Boston, MA – July 15, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive ...

1 year ago - GlobeNewsWire

 PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24

1 year ago - GlobeNewsWire

 ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that they will present at ESH...

1 year ago - GlobeNewsWire

About OBSV

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for pret... [Read more...]

Industry
Biotechnology
IPO Date
Jan 26, 2017
CEO
Ernest Loumaye
Employees
42
Stock Exchange
NASDAQ
Ticker Symbol
OBSV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for ObsEva stock is "Buy." The 12-month stock price forecast is 17.67, which is an increase of 601.19% from the latest price.

Price Target
$17.67
(601.19% upside)
Analyst Consensus: Buy